Full-Text Search:
Home|Journal Papers|About CNKI|User Service|FAQ|Contact Us|中文
《Practical Clinical Medicine》 2000-01
Add to Favorite Get Latest Update

Study on Expression of CD_(44)V_7/V_8 in Bladder transitional Carcinoma

HAN Binde 1,GE Gen 2,XI Xiaoqin 2,WU Qimin 3 (1.Department of Surgery,Pulmonary Hospital of Jiangxi,Nanchang 330006,China; 2.Department of Urology,Second Affiliated Hospital,Jiangxi Medical College,Nanchang 330006, China; 3.Department of Path  
Objective:To study the clinic significance of expression of CD 44 V 7/V 8 protein in transitional cell carcinoma of bladder.Methods:Using S-P immunohistochemical method with anti-CD 44 V 7/V 8 monoclonal antibody,we examine the expression of CD 44 V 7/V 8 in 42 fresh specimens of transitional cell bladder carcinoma and in 8 normal bladder tissues as control as well as its correlations with clinicopathologic factors .Results:The positive expression was distributed in cell membrance,cytoplasm,and stroma of bladder tumor tissues.The rate and intensity of CD 44 V 7/V 8 protein positive expression in bladder tumors were significantly higher than those in normal bladder tissues (P rate 0.05,P level 0.01).The rates of CD 44 V 7/V 8 protein positive expression in poor differentiated、invasive and recurrence bladder tumors were significantly higher than those in well differentiated、superficial and primary tumors ( P 0.05).The positive expression rate was not related with the age of patients and the number of tumors ( P 0.05),althongh it was related with the diameter size of tumor base ( P 0.05).Conclusions:CD 44 V 7/V 8 protein plays a critical role in progression、invasion and recurrence of transitional cell bladder carcinoma and might be useful for estimation of the prognosis of patients with transitional cell carcinoma of bladder.
【CateGory Index】: R737.14
Download(CAJ format) Download(PDF format)
CAJViewer7.0 supports all the CNKI file formats; AdobeReader only supports the PDF format.
©2006 Tsinghua Tongfang Knowledge Network Technology Co., Ltd.(Beijing)(TTKN) All rights reserved